Unfortunately, the patient was not eligible for ASCT because of severe bortezomib‐ and thalidomide‐induced neuropathy and JAK2‐mutated myeloproliferative neoplasm with marked splenomegaly. The gene discussed is JAK2; the disease is neuropathy.